Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.925 USD | -4.10% | +10.80% | +55.99% |
Valuation
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Capitalization 1 | 271.4 | 75.84 | 30.2 | 21.31 | 60.19 | - | - |
Enterprise Value (EV) 1 | 271.4 | 75.84 | 30.2 | 21.31 | 60.19 | 60.19 | 60.19 |
P/E ratio | -5.15 x | -1.6 x | -0.46 x | -0.53 x | -0.91 x | -0.83 x | -0.86 x |
Yield | - | - | - | - | - | - | - |
Capitalization / Revenue | - | - | - | - | - | - | 1.7 x |
EV / Revenue | - | - | - | - | - | - | 1.7 x |
EV / EBITDA | -7,925,679 x | - | - | - | - | - | - |
EV / FCF | -11.2 x | -2.16 x | - | - | -1.09 x | -0.77 x | -1.4 x |
FCF Yield | -8.96% | -46.3% | - | - | -91.8% | -130% | -71.6% |
Price to Book | - | - | - | - | - | - | - |
Nbr of stocks (in thousands) | 11,212 | 11,236 | 11,267 | 11,365 | 20,578 | - | - |
Reference price 2 | 24.21 | 6.750 | 2.680 | 1.875 | 2.925 | 2.925 | 2.925 |
Announcement Date | 3/11/21 | 3/9/22 | 3/8/23 | 3/13/24 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | - | - | 35.44 |
EBITDA | - | -34.25 | - | - | - | - | - | - |
EBIT 1 | -7.83 | -34.44 | -47.49 | -37.54 | -43.61 | -54.31 | -70.7 | -58.16 |
Operating Margin | - | - | - | - | - | - | - | -164.12% |
Earnings before Tax (EBT) 1 | - | -33.98 | -47.25 | -65.95 | -40.42 | -50.86 | -59.85 | -69.55 |
Net income 1 | - | -33.98 | -47.25 | -65.95 | -40.42 | -50.64 | -60.33 | -65.34 |
Net margin | - | - | - | - | - | - | - | -184.4% |
EPS 2 | - | -4.700 | -4.210 | -5.860 | -3.570 | -3.205 | -3.523 | -3.397 |
Free Cash Flow 1 | - | -24.32 | -35.1 | - | - | -55.24 | -78.38 | -43.09 |
FCF margin | - | - | - | - | - | - | - | -121.6% |
FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - | - | - |
Announcement Date | 3/11/21 | 3/11/21 | 3/9/22 | 3/8/23 | 3/13/24 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBIT 1 | -10.83 | -10.29 | -10.87 | -8.705 | -7.974 | -9.992 | -9.732 | -12.14 | -10.7 | -11.04 | -12.05 | -12.81 | -13.27 | -13.51 | - |
Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Earnings before Tax (EBT) 1 | -10.78 | -10.23 | -10.76 | -8.539 | -7.691 | -38.97 | -9.045 | -11.29 | -9.86 | -10.22 | -11.87 | -12.68 | -13.16 | -13.18 | - |
Net income 1 | -10.78 | -10.23 | -10.76 | -8.539 | -7.691 | -38.97 | -9.045 | -11.29 | -9.86 | -10.22 | -11.8 | -12.56 | -13.07 | -13.24 | - |
Net margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EPS 2 | -0.9600 | -0.9100 | -0.9600 | -0.8000 | -0.6800 | -3.460 | -0.8000 | -1.000 | -0.8700 | -0.9000 | -0.9200 | -0.8000 | -0.7650 | -0.7800 | - |
Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Announcement Date | 11/4/21 | 3/9/22 | 5/5/22 | 8/9/22 | 11/3/22 | 3/8/23 | 5/4/23 | 8/3/23 | 11/3/23 | 3/13/24 | - | - | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Net Debt | - | - | - | - | - | - | - | - |
Net Cash position | - | - | - | - | - | - | - | - |
Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
Free Cash Flow 1 | - | -24.3 | -35.1 | - | - | -55.2 | -78.4 | -43.1 |
ROE (net income / shareholders' equity) | - | - | - | - | - | - | - | - |
ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
Assets 1 | - | - | - | - | - | - | - | - |
Book Value Per Share | - | - | - | - | - | - | - | - |
Cash Flow per Share | - | - | - | - | - | - | - | - |
Capex 1 | - | 0.88 | 0.6 | - | - | 0.79 | 0.87 | 0.96 |
Capex / Sales | - | - | - | - | - | - | - | 2.71% |
Announcement Date | 3/11/21 | 3/11/21 | 3/9/22 | 3/8/23 | 3/13/24 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+55.99% | 33.44M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.73B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- TARA Stock
- Financials Protara Therapeutics, Inc.